ホーム › 非小細胞肺癌 › フロリダ州 › West Palm Beach
West Palm Beach、FLにおける非小細胞肺癌の臨床試験
West Palm Beachとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する13件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Florida Cancer Specialists - East /ID# 271993, West Palm Beach
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- Florida Cancer Specialists & Research Institute - East, West Palm Beach
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Florida Cancer Specialists - East, West Palm Beach
- Florida Cancer Specialists, Palm Beach Gardens · 9マイル先
- Florida Cancer Specialists, Wellington · 12マイル先
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Florida Cancer Specialists & Research Institute, West Palm Beach
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- Florida Cancer Specialists East, West Palm Beach
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, West Palm Beach
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
被験者募集中第3相
- Florida Cancer Specialists - East, West Palm Beach
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, West Palm Beach
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- SCRI - Florida Cancer Specialists - West Palm Beach, West Palm Beach
- Local Institution - 007-926-A, Wellington · 12マイル先
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
被験者募集中第1/2相
- Florida Cancer Specialists - EAST - SCRI - PPDS, West Palm Beach
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- Florida Cancer Specialists - EAST - SCRI - PPDS, West Palm Beach
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, West Palm Beach
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- USOR Florida Cancer Specialists East, West Palm Beach
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
West Palm Beachにおける他の研究
- アルツハイマー病13件の研究
- 肥満症11件の研究
- 卵巣がん11件の研究
- 過体重9件の研究
- 子宮内膜がん8件の研究
- 統合失調症7件の研究
- 心不全7件の研究
- 2型糖尿病7件の研究
- 心血管疾患7件の研究
- 大うつ病性障害7件の研究
- COPD6件の研究
- HIV6件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。